Annals of Oncology

Editorials:

R. Arriagada and J. Gutiérrez

Anthracyclines: is more, better and/or more dangerous?
Ann Oncol 14: 663-665; doi:10.1093/annonc/mdg220
[Extract] [FREE Full Text] [PDF] [Request Permissions]

Reviews:

H. Gogas and G. Fountzilas

The role of taxanes as a component of neoadjuvant chemotherapy for breast cancer
Ann Oncol 14: 667-674; doi:10.1093/annonc/mdg210
[Extract] [FREE Full Text] [PDF] [Request Permissions]

J. P. Neoptolemos, D. Cunningham, H. Friess, C. Bassi, D. D. Stocken, D. M. Tait, J. A. Dunn, C. Dervenis, F. Lacaine, H. Hickey, M. G. T. Raraty, P. Ghaneh, and M. W. Büchler

Adjuvant therapy in pancreatic cancer: historical and current perspectives
Ann Oncol 14: 675-692; doi:10.1093/annonc/mdg207
[Abstract] [FREE Full Text] [PDF] [Request Permissions]

Original articles:

Breast cancer:

C. Bernard-Marty, M. Mano, M. Paesmans, C. Accettura, R. Munoz-Bermeo, T. Richard, K. Kleiber, F. Cardoso, J. P. Lobelle, D. Larsimont, M. J. Piccart, and A. Di Leo

Second malignancies following adjuvant chemotherapy: 6-year results from a Belgian randomized study comparing cyclophosphamide, methotrexate and 5-fluorouracil (CMF) with an anthracycline-based regimen in adjuvant treatment of node-positive breast cancer patients
Ann Oncol 14: 693-698; doi:10.1093/annonc/mdg204
[Abstract] [FREE Full Text] [PDF] [Request Permissions]

I. Elomaa, H. Joensuu, and C. Blomqvist

Vinorelbine, methotrexate and fluorouracil (VMF) as first-line therapy in metastatic breast cancer: a randomized phase II trial
Ann Oncol 14: 699-703; doi:10.1093/annonc/mdg199
[Abstract] [FREE Full Text] [PDF] [Request Permissions]

P. Marchetti, K. Cannita, E. Ricevuto, F. De Galitiis, Z. C. Di Rocco, A. Tessitore, R. Bisegna, G. Porzio, G. P. De Rubeis, T. Ventura, S. Martinotti, and C. Ficorella

Prognostic value of p53 molecular status in high-risk primary breast cancer
Ann Oncol 14: 704-708; doi:10.1093/annonc/mdg197
[Abstract] [FREE Full Text] [PDF] [Request Permissions]

Lung cancer:

I. Sekine, Y. Nishiwaki, K. Noda, S. Kudoh, M. Fukuoka, K. Mori, S. Negoro, A. Yokoyama, K. Matsui, Y. Ohsaki, T. Nakano, and N. Saijo

Randomized phase II study of cisplatin, irinotecan and etoposide combinations administered weekly or every 4 weeks for extensive small-cell lung cancer (JCOG9902-DI)
Ann Oncol 14: 709-714; doi:10.1093/annonc/mdg213
[Abstract] [FREE Full Text] [PDF] [Request Permissions]

T. Berghmans, A. P. Meert, C. Mascaux, M. Paesmans, J. J. Lafitte, and J. P. Sculier

Citation indexes do not reflect methodological quality in lung cancer randomised trials
Ann Oncol 14: 715-721; doi:10.1093/annonc/mdg203
[Abstract] [FREE Full Text] [PDF] [Request Permissions]

A. M. Mauer, R. H. Ansari, P. C. Hoffman, S. A. Krauss, D. Taber, S. A. Tembe, G. T. Gabrys, T. Cotter, L. P. Schumm, L. Szeto, and E. E. Vokes

Phase I/II investigation of paclitaxel, ifosfamide and carboplatin for advanced non-small-cell lung cancer
Ann Oncol 14: 722-728; doi:10.1093/annonc/mdg212
[Abstract] [FREE Full Text] [PDF] [Request Permissions]

Hematologic malignancies:

R. Schnell, P. Borchmann, J. O. Staak, J. Schindler, V. Ghetie, E. S. Vitetta, and A. Engert

Clinical evaluation of ricin A-chain immunotoxins in patients with Hodgkin’s lymphoma
Ann Oncol 14: 729-736; doi:10.1093/annonc/mdg209
[Abstract] [FREE Full Text] [PDF] [Request Permissions]

C. Hosing, R. M. Saliba, P. McLaughlin, B. Andersson, M. A. Rodriguez, L. Fayad, F. Cabanillas, R. E. Champlin, and I. F. Khouri

Long-term results favor allogeneic over autologous hematopoietic stem cell transplantation in patients with refractory or recurrent indolent non-Hodgkin’s lymphoma
Ann Oncol 14: 737-744; doi:10.1093/annonc/mdg200
[Abstract] [FREE Full Text] [PDF] [Request Permissions]

M. Constans, A. Sureda, M. J. Terol, R. Arranz, M. D. Caballero, A. Iriondo, I. Jarque, E. Carreras, J. M. Moraleda, D. Carrera, A. León, A. López, C. Albó, J. Díaz-Mediavilla, P. Fernández-Abellán, J. C. García-Ruiz, F. Hernández-Navarro, R. Mataix, J. Petit, M. J. Pascual, J. Rifón, J. García-Conde, J. M. Fernández-Rañada, M. V. Mateos, J. Sierra, and E. Conde

Autologous stem cell transplantation for primary refractory Hodgkin’s disease: results and clinical variables affecting outcome
Ann Oncol 14: 745-751; doi:10.1093/annonc/mdg206
[Abstract] [FREE Full Text] [PDF] [Request Permissions]

W. Y. Au, A. K. W. Lie, C. S. Chim, R. Liang, S. K. Ma, C. H. Chan, Y. K. Mak, Y. T. Chen, C. C. So, Y. M. Yeung, S. F. Yip, L. G. Wong, J. C. Chan, S. Y. Liu, and Y. L. Kwong

Arsenic trioxide in comparison with chemotherapy and bone marrow transplantation for the treatment of relapsed acute promyelocytic leukaemia
Ann Oncol 14: 752-757; doi:10.1093/annonc/mdg208
[Abstract] [FREE Full Text] [PDF] [Request Permissions]

Phase I and pharmacokinetics:

J. Mangel, R. Buckstein, K. Imrie, D. Spaner, E. Franssen, P. Pavlin, A. Boudreau, N. Pennell, D. Combs, and N. L. Berinstein

Pharmacokinetic study of patients with follicular or mantle cell lymphoma treated with rituximab as ‘in vivo purge’ and consolidative immunotherapy following autologous stem cell transplantation
Ann Oncol 14: 758-765; doi:10.1093/annonc/mdg201
[Abstract] [FREE Full Text] [PDF] [Request Permissions]

D. J. Stewart, R. C. Donehower, E. A. Eisenhauer, N. Wainman, A. K. Shah, C. Bonfils, A. R. MacLeod, J. M. Besterman, and G. K. Reid

A phase I pharmacokinetic and pharmacodynamic study of the DNA methyltransferase 1 inhibitor MG98 administered twice weekly
Ann Oncol 14: 766-774; doi:10.1093/annonc/mdg216
[Abstract] [FREE Full Text] [PDF] [Request Permissions]

G. H. Schwartz, A. Patnaik, L. A. Hammond, J. Rizzo, K. Berg, D. D. Von Hoff, and E. K. Rowinsky

A phase I study of bizelesin, a highly potent and selective DNA-interactive agent, in patients with advanced solid malignancies
Ann Oncol 14: 775-782; doi:10.1093/annonc/mdg215
[Abstract] [FREE Full Text] [PDF] [Request Permissions]

D. Castellano, R. Hitt, E. Ciruelos, H. Cortés-Funes, and R. Colomer

Biweekly vinorelbine and gemcitabine: a phase I dose-finding study in patients with advanced solid tumors
Ann Oncol 14: 783-787; doi:10.1093/annonc/mdg196
[Abstract] [FREE Full Text] [PDF] [Request Permissions]

P. L. R. Mitchell, R. Basser, M. Chipman, A. Grigg, J. Cebon, I. D. Davis, J. Zalcberg, S. Ng, F. Appia, and M. Green

A phase I dose-escalation study of docetaxel with granulocyte colony-stimulating factor support in patients with solid tumours
Ann Oncol 14: 788-794; doi:10.1093/annonc/mdg202
[Abstract] [FREE Full Text] [PDF] [Request Permissions]

Supportive care:

P. F. Smith, M. C. Birmingham, G. A. Noskin, A. K. Meagher, A. Forrest, C. R. Rayner, and J. J. Schentag

Safety, efficacy and pharmacokinetics of linezolid for treatment of resistant Gram-positive infections in cancer patients with neutropenia
Ann Oncol 14: 795-801; doi:10.1093/annonc/mdg211
[Abstract] [FREE Full Text] [PDF] [Request Permissions]

Letters to the Editor:

S. Di Cosimo, G. Ferretti, N. Fazio, M. Mandalà, G. Curigliano, S. Bosari, M. Intra, A. Latronico, and A. Goldhirsch

Breast and ovarian metastatic localization of signet-ring cell gastric carcinoma
Ann Oncol 14: 803-804; doi:10.1093/annonc/mdg218
[Extract] [FREE Full Text] [PDF] [Request Permissions]

B. Coiffier

Advocating recombinant human erythropoietin as standard practice in Europe for treatment of cancer-related anaemia
Ann Oncol 14: 804; doi:10.1093/annonc/mdg214
[Extract] [FREE Full Text] [PDF] [Request Permissions]

G. Fiorentini, S. Rossi, G. Lanzanova, P. Bernardeschi, P. Dentico, and U. De Giorgi

Potential use of imatinib mesylate in ocular melanoma and liposarcoma expressing immunohistochemical c-KIT (CD117)
Ann Oncol 14: 805; doi:10.1093/annonc/mdg192
[Extract] [FREE Full Text] [PDF] [Request Permissions]

A. Alimonti, F. Satta, I. Pavese, E. Burattini, V. Zoffoli, and A. Vecchione

Prevention of irinotecan plus 5-fluorouracil/leucovorin-induced diarrhoea by oral administration of neomycin plus bacitracin in first-line treatment of advanced colorectal cancer
Ann Oncol 14: 805-806; doi:10.1093/annonc/mdg193
[Extract] [FREE Full Text] [PDF] [Request Permissions]

B. Vincenzi, D. Santini, L. Rocci, and G. Tonini

Bisphosphonates: new antiangiogenic molecules in cancer treatment?
Ann Oncol 14: 806-807; doi:10.1093/annonc/mdg194
[Extract] [FREE Full Text] [PDF] [Request Permissions]

Book reviews:

A. A. Brandes

D. Schiff, P.Y. Wen (eds). Cancer Neurology in Clinical Practice
Ann Oncol 14: 809; doi:10.1093/annonc/mdg205
[Extract] [FREE Full Text] [PDF] [Request Permissions]

C. J. A. Punt

E.C. Borden (ed). Melanoma: Biologically Targeted Therapeutics
Ann Oncol 14: 809-810; doi:10.1093/annonc/mdg195
[Extract] [FREE Full Text] [PDF] [Request Permissions]

A. Zaniboni

D.J. Kerr, W. Bodmer, C. McArdle, M. Pignatelli (eds). Advances in Colorectal Cancer
Ann Oncol 14: 810; doi:10.1093/annonc/mdg217
[Extract] [FREE Full Text] [PDF] [Request Permissions]

Corrigenda:

M. S. Aapro, F. H. van Wijk, G. Bolis, B. Chevallier, M. E. L. van der Burg, A. Poveda, C. F. de Oliveira, S. Tumolo, V. Scotto di Palumbo, M. Piccart, M. Franchi, F. Zanaboni, A. J. Lacave, R. Fontanelli, G. Favalli, P. Zola, J. P. Guastalla, R. Rosso, C. Marth, M. Nooij, M. Presti, C. Scarabelli, T. A. W. Splinter, E. Ploch, L. V. A. Beex, W. ten Bokkel Huinink, M. Forni, M. Melpignano, P. Blake, P. Kerbrat, C. Mendiola, A. Cervantes, A. Goupil, P. G. Harper, C. Madronal, M. Namer, G. Scarfone, J. E. G. M. Stoot, I. Teodorovic, C. Coens, I. Vergote, and J. B. Vermorken

Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer GroupAnn Oncol 2003; 14: 441–448
Ann Oncol 14: 811; doi:10.1093/annonc/mdg221
[Extract] [FREE Full Text] [PDF] [Request Permissions]

To see an article, click its [Full Text] or [PDF] link. To review many abstracts, check the boxes to the left of the titles you want, and click the 'Get All Checked Abstract(s)' button. To see one abstract at a time, click its [Abstract] link.